U.S. Diabetes MSImage Study
Given the rising global epidemic of diabetes, pharmaceutical, biotech and device companies continue to invest heavily in this marketplace. The number of products in research and development for diabetes is second only to oncology, and nearly every leading manufacturer wants to be a player in this market. To navigate this highly competitive environment, companies need compelling market intelligence to ensure success.
Market Strategies’ U.S. Diabetes MSImage Study measures the image of ten diabetes drug manufacturers among three key U.S.-based stakeholders: endocrinologists, primary care physicians and diabetic nurse educators.
Specific information available in the survey includes:
- Which pharmaceutical company has the best image
- Where your company ranks in overall image
- How your company ranks in key performance measures
- Where your competitors are leading and trailing in key performance measures
- Which key performance measures drive overall image
- How important each key performance measure is to your customers
- Where your diabetes franchise should focus future efforts
|
Subscribers to the U.S. Diabetes MSImage Study will receive a thorough analysis of results in PowerPoint including an executive summary, detailed findings and presentation-ready graphics, an executive summary customized to your company and an in-person presentation of results, if desired.
Market Strategies conducted the online study with 400 diabetes stakeholders including 100 endocrinologists, 100 diabetes nurse educators and 150 primary care physicians. The analysis was completed at the individual stakeholder level to explore differences. We fielded the study in the summer of 2010.
For more information or to purchase the study contact:
Katy Palmer, Ph.D.
Senior Vice President, Healthcare Division
734.542.7746